The capital priced a lifespan drug. SELECT enrolled a cardiovascular trial. SELECT (NCT03574597, Novo Nordisk funded, n=17,604, median follow-up 33.8 months) enrolled adults with established cardiovascular disease, BMI of 27 or above, and no prior type 2 diabetes; its primary endpoint was major adverse cardiovascular events. The result, published in the NEJM in November 2023, was a 20% relative risk reduction in MACE. The family-office GLP-1 position is pricing the same molecule against a different primary endpoint, in a different population, on a mechanism the trial was not designed to test. The SELECT population and the longevity-consumer population share a drug. They do not share a hypothesis.

The regulatory architecture makes the gap precise. Neither FDA's Center for Drug Evaluation and Research nor NMPA's Center for Drug Evaluation has qualified a biological age surrogate as a primary endpoint in a drug approval application. TGA's Advisory Committee on Medicines has reviewed semaglutide and tirzepatide submissions on metabolic and cardiovascular grounds exclusively. The only active trial using aging itself as the indication is TAME, studying metformin under a composite endpoint of incident age-related diseases and all-cause mortality, n=3,000 target enrolment, funded by the American Federation for Aging Research. No GLP-1 trial matches that design. The position runs on a bet that cardiovascular event reduction maps to lifespan extension. CDER has not confirmed that mapping, and the Biomarker Qualification Program's list of accepted surrogate endpoints for aging currently has zero entries.